365 related articles for article (PubMed ID: 27170195)
1. The effect of an abuse-deterrent opioid formulation (OxyContin) on opioid abuse-related outcomes in the postmarketing setting.
Coplan PM; Chilcoat HD; Butler SF; Sellers EM; Kadakia A; Harikrishnan V; Haddox JD; Dart RC
Clin Pharmacol Ther; 2016 Sep; 100(3):275-86. PubMed ID: 27170195
[TBL] [Abstract][Full Text] [Related]
2. Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone.
Severtson SG; Ellis MS; Kurtz SP; Rosenblum A; Cicero TJ; Parrino MW; Gilbert MK; Buttram ME; Dasgupta N; BucherBartelson B; Green JL; Dart RC
Drug Alcohol Depend; 2016 Nov; 168():219-229. PubMed ID: 27716575
[TBL] [Abstract][Full Text] [Related]
3. Decreased diversion by doctor-shopping for a reformulated extended release oxycodone product (OxyContin).
Chilcoat HD; Coplan PM; Harikrishnan V; Alexander L
Drug Alcohol Depend; 2016 Aug; 165():221-8. PubMed ID: 27372220
[TBL] [Abstract][Full Text] [Related]
4. Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin.
Cicero TJ; Ellis MS
JAMA Psychiatry; 2015 May; 72(5):424-30. PubMed ID: 25760692
[TBL] [Abstract][Full Text] [Related]
5. Evaluating the potential impact of a reformulated version of oxycodone upon tampering, non-adherence and diversion of opioids: the National Opioid Medications Abuse Deterrence (NOMAD) study protocol.
Degenhardt L; Larance B; Bruno R; Lintzeris N; Ali R; Farrell M
Addiction; 2015 Feb; 110(2):226-37. PubMed ID: 25358480
[TBL] [Abstract][Full Text] [Related]
6. Incidence of nonmedical use of OxyContin and other prescription opioid pain relievers before and after the introduction of OxyContin with abuse deterrent properties.
Cheng HG; Coplan PM
Postgrad Med; 2018 Aug; 130(6):568-574. PubMed ID: 29978755
[TBL] [Abstract][Full Text] [Related]
7. Adverse health effects of abuse-deterrent opioids: Evidence from the reformulation of OxyContin.
Beheshti D
Health Econ; 2019 Dec; 28(12):1449-1461. PubMed ID: 31715653
[TBL] [Abstract][Full Text] [Related]
8. Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics.
Coplan PM; Kale H; Sandstrom L; Landau C; Chilcoat HD
Pharmacoepidemiol Drug Saf; 2013 Dec; 22(12):1274-82. PubMed ID: 24123484
[TBL] [Abstract][Full Text] [Related]
9. Monitoring of internet forums to evaluate reactions to the introduction of reformulated OxyContin to deter abuse.
McNaughton EC; Coplan PM; Black RA; Weber SE; Chilcoat HD; Butler SF
J Med Internet Res; 2014 May; 16(5):e119. PubMed ID: 24800858
[TBL] [Abstract][Full Text] [Related]
10. Opioid addiction, diversion, and abuse in chronic and cancer pain.
Kata V; Novitch MB; Jones MR; Anyama BO; Helander EM; Kaye AD
Curr Opin Support Palliat Care; 2018 Jun; 12(2):124-130. PubMed ID: 29465470
[TBL] [Abstract][Full Text] [Related]
11. Impact of abuse-deterrent OxyContin on prescription opioid utilization.
Hwang CS; Chang HY; Alexander GC
Pharmacoepidemiol Drug Saf; 2015 Feb; 24(2):197-204. PubMed ID: 25393216
[TBL] [Abstract][Full Text] [Related]
12. Abuse of reformulated OxyContin: Updated findings from a sentinel surveillance sample of individuals assessed for substance use disorder.
Cassidy TA; Thorley E; Black RA; DeVeaugh-Geiss A; Butler SF; Coplan P
J Opioid Manag; 2017; 13(6):425-440. PubMed ID: 29308589
[TBL] [Abstract][Full Text] [Related]
13. Protocol: changes in rates of opioid overdose and poisoning events in an integrated health system following the introduction of a formulation of OxyContin® with abuse-deterrent properties.
Janoff SL; Perrin NA; Coplan PM; Chilcoat HD; Campbell CI; Green CA
BMC Pharmacol Toxicol; 2016 May; 17(1):21. PubMed ID: 27177423
[TBL] [Abstract][Full Text] [Related]
14. Attractiveness of reformulated OxyContin(R) tablets: assessing comparative preferences and tampering potential.
Sellers EM; Perrino PJ; Colucci SV; Harris SC
J Psychopharmacol; 2013 Sep; 27(9):808-16. PubMed ID: 23784739
[TBL] [Abstract][Full Text] [Related]
15. Use of prescription opioids with abuse-deterrent technology to address opioid abuse.
Michna E; Kirson NY; Shei A; Birnbaum HG; Ben-Joseph R
Curr Med Res Opin; 2014 Aug; 30(8):1589-98. PubMed ID: 24738694
[TBL] [Abstract][Full Text] [Related]
16. The impact of a reformulation of extended-release oxycodone designed to deter abuse in a sample of prescription opioid abusers.
Havens JR; Leukefeld CG; DeVeaugh-Geiss AM; Coplan P; Chilcoat HD
Drug Alcohol Depend; 2014 Jun; 139():9-17. PubMed ID: 24721614
[TBL] [Abstract][Full Text] [Related]
17. Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment.
Butler SF; Cassidy TA; Chilcoat H; Black RA; Landau C; Budman SH; Coplan PM
J Pain; 2013 Apr; 14(4):351-8. PubMed ID: 23127293
[TBL] [Abstract][Full Text] [Related]
18. Opioids with abuse-deterrent properties: A regulatory and technological overview.
Haddox JD
J Opioid Manag; 2017; 13(6):397-413. PubMed ID: 29308587
[TBL] [Abstract][Full Text] [Related]
19. Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation.
Sessler NE; Downing JM; Kale H; Chilcoat HD; Baumgartner TF; Coplan PM
Pharmacoepidemiol Drug Saf; 2014 Dec; 23(12):1238-46. PubMed ID: 24916486
[TBL] [Abstract][Full Text] [Related]
20. Rates of opioid dispensing and overdose after introduction of abuse-deterrent extended-release oxycodone and withdrawal of propoxyphene.
Larochelle MR; Zhang F; Ross-Degnan D; Wharam JF
JAMA Intern Med; 2015 Jun; 175(6):978-87. PubMed ID: 25895077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]